Loading...

About Us

 We are a privately-held biotechnology company located in Huntersville, North Carolina focused on Cancer Immunotherapy.

Contract Services

We collaborate with industry leaders by contributing to translational research, biospecimen banking and procurement, & cell manufacturing.

Clinical Trials

Our expert Providers participate in national clinical trials to advance cancer immunotherapy research and to help bring novel therapies to patients.

Science + Pipeline

Our portfolio of nonclinical cell therapy programs leverages the intrinsic specificity of autologous immune cells to potentially treat solid tumors.

*Patient infusion of cell therapy products not currently performed.

These products and their uses are investigational and have not been proven to be safe or been approved by the U.S. Food and Drug Administration (FDA).

View Our Facilities

In The News

Strategic Collaboration to Develop Advanced Cancer Screening Platforms and Companion Diagnostics

BioCytics and LIDE Biotech Initiate Pilot Project to Develop PDX Cancer Models – 8/13/26

BioCytics, Inc., and LIDE Biotech are proud to announce the formation of a strategic alliance to develop advanced screening platforms and companion diagnostics for immune-based cancer cell therapies. This collaboration combines BioCytics’ specialized cell manufacturing capabilities with LIDE’s unique, patient-derived xenograft technologies (PDX, miniPDX®, and IO-based PDX models) to streamline the development of immuno-oncology (IO) treatments.

Unlocking the Dark Genome of Cancer: A Landmark Collaboration Between BioCytics and UNC Charlotte

Collaboration with UNC Charlotte – 7/20/26

BioCytics and UNC Charlotte, along with Carolina BioOncology Institute, are embarking on a new project to study as-yet unidentified sequences in the human genome that might be responsible for cancer cell growth and treatment response.  BioCytics’ Chief Scientific Officer, Dr. Renaud Warin, and UNC Charlotte Associate Professor, Dr. Richard White III, are embarking on a collaboration that involves studying the “dark genome” of cancer cells.  The dark genome is the portion of the genome (approximately 98%) that does not directly code for a protein.  The goal of this project is to identify viral and immune sequences involved in the progression of cancer and immune response to cancer.

Dr. John Powderly Heads Discussion Group at openEHR International and HL7’s 2026 “Converge and Collaborate” Meeting

Converge and Collaborate – 5/14/26

On May 12th and 13th in Dublin, Ireland, openEHR International and HL7 (Health Level Seven) hosted their second annual in-person meeting called “Converge and Collaborate”.  With an overall focus on cancer treatment support, this meeting also had the broader aim of increasing the collaborative agenda at the heart of these two organizations, which is improving interoperability for healthcare data exchange.

Dr. John Powderly, President and CEO of both Carolina BioOncology Institute and BioCytics, led a working group discussion around the idea of the convergence of Clinical Research and Informatics. He was also able to explain to an interested audience about the openEHR Affiliate Program, which allows any country or specific field in the medical/health sciences to form a group as part of openEHR International.  These Affiliate Groups help with digital transformation initiatives in all areas where clinical data standards are used or needed.

Dr. Powderly Keynote Speaker at “Hope is Not a Workflow” Symposium

Hope is Not a Workflow – 3/25/26

Dr. Powderly was recently a Keynote Speaker at an event organized by “Hope is Not a Workflow” cell and gene therapy (C&GT) stakeholder collective partnership.  Taking place on March 25, 2026, in Research Triangle Park, the daylong symposium focused on advancing manufacturing for C&GT.